ArticleThe American journal of emergency medicine2020
Neuroleptic malignant syndrome in patients with COVID-19.
Article in The American journal of emergency medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Toxicity of psychotropic drugs in patients with COVID-19: A systematic review.General hospital psychiatryPooled it
- Acute Febrile Encephalopathy with Rigidity.Journal of intensive care medicine · 2026Review
- Neuroleptic malignant syndrome in a patient with COVID-19 and the possible role of SARS-CoV-2 in its manifestation: case report and overview of published cases.BMC psychiatry · 2025Review
- Neuroleptic malignant syndrome requiring intensive care unit admission in two patients with SARS-CoV-2 infection in Portugal.Acute and critical care · 2025Article
- Neuroleptic Malignant Syndrome Concurrent with COVID-19 Infection: A Case Report.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2024Article
- A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system.Frontiers in pharmacology · 2024Article
- The diagnostic dilemma in a patient with neuroleptic malignant syndrome during the COVID-19 pandemic: A significant increase in acute phase reactants.Clinical case reports · 2023Article
- Hyperpyrexia in a previously healthy pregnant female with COVID pneumonia: a case report and review of the literature.Journal of medical case reports · 2023Review
- [Central anticholinergic, neuroleptic malignant and serotonin syndromes : Important differential diagnoses in postoperative impairment of consciousness].Die Anaesthesiologie · 2023Review
- [Central anticholinergic, neuroleptic malignant and serotonin syndromes].Wiener klinisches Magazin : Beilage zur Wiener klinischen Wochenschrift · 2023Review
- On Patterns of Neuropsychiatric Symptoms in Patients With COVID-19: A Systematic Review of Case Reports.Cureus · 2022Review
- A Case of Neuroleptic Malignant Syndrome After COVID-19 Vaccination and Possible Mechanisms of Vaccines in the Formation of This Syndrome.Psychiatry and clinical psychopharmacology · 2022Article
- Neuroleptic malignant syndrome following COVID-19 vaccination.The American journal of emergency medicine · 2021Article
- Propofol in COVID 19 - From basic science to clinical impact.The American journal of emergency medicine · 2021Article
- The authors' response: A diagnostic confusion between serotonin syndrome and neuroleptic malignant syndrome.The American journal of emergency medicine · 2021Article
- Putative antiviral effects of propofol in COVID-19.British journal of anaesthesia · 2021Article
- A diagnostic confusion between Serotonin syndrome and Neuroleptic malignant syndrome.The American journal of emergency medicine · 2021Article
- Neuroleptic malignant syndrome in COVID-19 patients by Soh et al.The American journal of emergency medicine · 2021Article
- Propofol and sedation in patients with coronavirus disease.The American journal of emergency medicine · 2021Article
- The authors' response: Propofol and sedation in patients with coronavirus disease 2019.The American journal of emergency medicine · 2021Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the first two cases of Coronavirus Disease 2019 (COVID-19) who were receiving intensive care including favipiravir, and were clinically diagnosed with neuroleptic malignant syndrome (NMS) to focus attention on NMS in COVID-19 management. Case 1: A 46-year-old-man with acute respiratory distress syndrome (ARDS) caused by COVID-19 infection was being administered favipiravir. Fentanyl, propofol, and rocuronium were also given. On day 3, midazolam administration was initiated for deep sedation. On day 5, his high body temperature increased to 41.2 °C, creatine kinase level elevated, and he developed tachycardia, tachypnea, altered consciousness, and diaphoresis. NMS was suspected, and supportive therapy was initiated. High-grade fever persisted for 4 days and subsided on day 9. Case 2: A 44-year-old-man with ARDS caused by COVID-19 infection was being treated with favipiravir. On day 5, risperidone was started for delirium. On day 7, his body temperature suddenly increased to 40.8 °C, his CK level elevated, and he developed tachycardia, tachypnea, altered consciousness, and diaphoresis. NMS diagnosis was confirmed, and both, favipiravir and risperidone were discontinued on day 8. On the same day, his CK levels decreased, and his body temperature normalized on day 9. Patients with COVID-19 infection frequently require deep sedation and develop delirium; therefore, more attention should be paid to the development of NMS in patients who are being administered such causative agents. The mechanism underlying the occurrence of NMS in COVID-19 patients treated with favipiravir remains unknown. Therefore, careful consideration of NMS development is necessary in the management of COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.